• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    8/14/25 1:06:04 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    GRAIL, Inc.

    (Name of Issuer)


    COM

    (Title of Class of Securities)


    384747101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    384747101


    1Names of Reporting Persons

    PRIMECAP MANAGEMENT CO/CA/
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,027,466.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,057,089.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,057,089.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.72 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GRAIL, Inc.
    (b)Address of issuer's principal executive offices:

    1525 O'BRIEN DRIVE, MENLO PARK, CALIFORNIA 94025
    Item 2. 
    (a)Name of person filing:

    PRIMECAP MANAGEMENT CO/CA/
    (b)Address or principal business office or, if none, residence:

    177 EAST COLORADO BLVD. 11TH FLOOR PASADENA, California 91105
    (c)Citizenship:

    PRIMECAP MANAGEMENT CO/CA/ - UNITED STATES
    (d)Title of class of securities:

    COM
    (e)CUSIP No.:

    384747101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,057,089
    (b)Percent of class:

    5.72  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    PRIMECAP MANAGEMENT CO/CA/ - 2,027,466

     (ii) Shared power to vote or to direct the vote:

    PRIMECAP MANAGEMENT CO/CA/ - 0

     (iii) Sole power to dispose or to direct the disposition of:

    PRIMECAP MANAGEMENT CO/CA/ - 2,057,089

     (iv) Shared power to dispose or to direct the disposition of:

    PRIMECAP MANAGEMENT CO/CA/ - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    PRIMECAP MANAGEMENT CO/CA/
     
    Signature:Jorge A. Rodriguez
    Name/Title:Deputy Chief Compliance Officer
    Date:08/14/2025
    Get the next $GRAL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ragusa Robert P sold $498,622 worth of shares (7,239 units at $68.88), decreasing direct ownership by 0.99% to 727,388 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/16/25 6:18:02 PM ET
    $GRAL
    Medical Specialities
    Health Care

    President Ofman Joshua J. sold $1,175,394 worth of shares (14,979 units at $78.47), decreasing direct ownership by 4% to 381,818 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/16/25 6:17:50 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Director Mizell Steven was granted 267 shares, increasing direct ownership by 0.74% to 36,469 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/16/25 6:17:56 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    SEC Filings

    View All

    GRAIL Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GRAIL, Inc. (0001699031) (Filer)

    10/16/25 5:02:13 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 144 filed by GRAIL Inc.

    144 - GRAIL, Inc. (0001699031) (Subject)

    10/14/25 6:09:08 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

    10/6/25 7:15:05 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL, Inc. Announces $325.0 Million Private Placement Financing

    MENLO PARK, Calif., Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents' fees and other expenses. The private placement included the participation by new and existing institutional investors, including Deep Track Capital, Farallon Capital Management, Hims & Hers, Braidwell LP, three li

    10/20/25 6:30:00 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL and University of Oxford to Present Long-Term Data From the SYMPLIFY Study Evaluating the Galleri® Multi-Cancer Early Detection Test in Symptomatic Individuals at the Early Detection of Cancer Conference (EDCC)

    One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up Updated Positive Predictive Value of Galleri in This Symptomatic Population was 84.2% Galleri Accurately Predicted the Location of the Cancer in Almost All Cases Initially Considered as False Positives, Reinforcing the Value of Galleri's CSO Capability MENLO PARK, Calif. and OXFORD, United Kingdom, Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and the University of Oxford, today announced that positive long-term results from an extended registry follow-up of the SYMPLIFY st

    10/20/25 6:00:00 AM ET
    $GRAL
    Medical Specialities
    Health Care

    /U P D A T E -- GRAIL, Inc./

    In the news release, GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings, issued 17-Oct-2025 by GRAIL, Inc. over PR Newswire, we are advised by the company that updated media assets have been attached to the news release. The complete, updated release follows: GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do N

    10/17/25 6:08:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on GRAIL with a new price target

    Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

    4/21/25 8:38:45 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Morgan Stanley initiated coverage on GRAIL with a new price target

    Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

    11/27/24 7:29:05 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Wolfe Research initiated coverage on GRAIL

    Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

    11/15/24 7:46:11 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    /U P D A T E -- GRAIL, Inc./

    In the news release, GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings, issued 17-Oct-2025 by GRAIL, Inc. over PR Newswire, we are advised by the company that updated media assets have been attached to the news release. The complete, updated release follows: GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do N

    10/17/25 6:08:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings

    More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population  MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. 

    10/17/25 6:08:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports Second Quarter 2025 Financial Results

    Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025. Total revenue in the second quarter grew 11% year-over-year to $35.5 million, and Galleri revenue gr

    8/12/25 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care